Guest: Edward S. Kim, MD <br>


  <p>RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.</p>

Guest: Edward S. Kim, MD RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

An Overview of RET Mutations in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by

Medicine

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;Sponsored by

Share An Overview of RET Mutations in NSCLC

Sign up to save your podcasts

An Overview of RET Mutations in NSCLC

An Overview of RET Mutations in NSCLC